Isomorphic Labs, a spinoff of Google DeepMind, announced that its AI-designed drugs are progressing to human trials. President Max Jaderberg shared the news at WIRED Health in London, highlighting a “broad and exciting pipeline of new medicines.” The development builds on DeepMind’s AlphaFold platform.
Isomorphic Labs president Max Jaderberg stated at WIRED Health in London that the startup has developed a “broad and exciting pipeline of new medicines” designed using artificial intelligence. These drugs, created with technology stemming from Google DeepMind, are now set to enter human trials to test their safety and effectiveness. Isomorphic Labs emerged as a spinoff from Google DeepMind, focusing on applying AI to drug discovery. Google DeepMind’s AlphaFold has transformed scientists’ understanding of proteins by predicting their structures with unprecedented accuracy. Jaderberg’s announcement marks the next phase, shifting from protein modeling to actual drug design and clinical testing. The move comes as biotech firms increasingly turn to AI to accelerate medicine development. Officials at Isomorphic Labs emphasized the potential of their pipeline, though specifics on the drugs or trial timelines remain undisclosed.
